verapamil has been researched along with Basal Ganglia Diseases in 1 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "2." | 1.30 | Evidence of sex related differences in the effects of calcium channel blockers on neuroleptic-induced catalepsy in mice. ( Amorim, SC; Costa, PG; Futuro-Neto, HA; Pires, JG; Ribeiro, CA; Saraiva, FP, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Futuro-Neto, HA | 1 |
| Costa, PG | 1 |
| Amorim, SC | 1 |
| Saraiva, FP | 1 |
| Ribeiro, CA | 1 |
| Pires, JG | 1 |
1 other study available for verapamil and Basal Ganglia Diseases
| Article | Year |
|---|---|
Evidence of sex related differences in the effects of calcium channel blockers on neuroleptic-induced catalepsy in mice.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Calcium Channel Blockers; Catalepsy; Dose-Res | 1999 |